Becton, Dickinson and Company (NYSE:BDX) reported $5 billion in revenue for the third quarter of fiscal 2026, marking a 4.4% increase on an FX-neutral basis as operational productivity and key platform growth propelled the company past analyst expectations.
A Focused Medical Technology Powerhouse
Chairman, CEO, and President Tom Polen highlighted this quarter as the company’s first full period operating exclusively as a focused medical technology firm following the separation of its life sciences division. According to Polen, over 90% of the company’s portfolio achieved high-single-digit growth, with several specific platforms delivering double-digit gains.
The company reported an adjusted operating margin of 24.9%, while adjusted diluted earnings per share (EPS) climbed 4.9% to $3.23. Reflecting this momentum, BD raised its full-year adjusted EPS outlook to a range of $12.62 to $12.72.
Growth Drivers Across Key Segments
Performance was bolstered by double-digit growth in biologic drug delivery, advanced patient monitoring, PureWick, and advanced tissue regeneration. The company also noted significant success in peripheral vascular disease treatments and Rowa pharmacy automation.
CFO Vitor Roque detailed the segment performances: Medical Essentials revenue grew 3.2%, aided by recovery in fluid utilization and gains in vascular access management. Specimen management saw high-single-digit growth, driven by the BD Vacutainer portfolio. Meanwhile, Connected Care revenue rose 4.4%, fueled by advanced patient monitoring, and BioPharma Systems increased 5.2%, largely due to GLP-1 program demand.
Strategic Investments and Global Collaboration
BD continues to lean into high-growth categories. Polen revealed that the company has secured approximately 100 agreements related to novel and biosimilar GLP-1 programs. A notable highlight includes a strategic collaboration with Brazilian pharmaceutical company EMS to launch a semaglutide therapy utilizing BD’s Vystra injection pen.
Commercial investments remain a priority, with the company expanding its U.S. advanced patient monitoring sales force by roughly 15% and bolstering the Veterans Affairs channel for PureWick. Recent product launches, such as the Liverty TIPS Stent Graft in Europe and the Elyra Thulium Fiber Laser System, further strengthen the company’s market position.
Operational Efficiency and Financial Health
Despite a 100-basis-point impact from tariffs, BD maintained strong productivity, generating approximately 8% gross productivity in its plants through consolidations and waste reduction. Service levels surpassed 90%, with back orders reaching record lows.
Year-to-date free cash flow surged 45% to $1.7 billion. The company has returned $3.1 billion to shareholders in the current fiscal year, split between share repurchases and dividends. Net leverage finished the quarter at approximately 2.9 times.
Fiscal Outlook and Leadership Transitions
For the remainder of fiscal 2026, BD anticipates revenue growth toward the high end of its low-single-digit FX-neutral range. Looking toward 2027, the company views low-single-digit growth as a realistic baseline as it moves past Alaris remediation headwinds.
The company also announced a leadership transition: Executive Vice President Mike Garrison will retire after two decades of service, while Peter Menziuso has joined as the new Executive Vice President and President of BD Interventional.
Deixe um comentário